Delisted from the New OTC Market for 8 days, with continuous losses and a debt ratio of 77%, 60% of the equity of Kangjuren was valued at nearly 100 million and merged into Corfu Medical | M&A frontline
Well-informed and knowledgeable
2026.11.20 21:31
· From Beijing
Full text 2645 words
On November 19, Corfu Medical (301087.SZ) announced that it planned to acquire 60% equity of Hefei Kangjuren Medical Device Technology Co., Ltd. with its own funds of 99.48 million yuan. After the transaction is completed, the target will be included in the consolidated statements.
The target of this acquisition of nearly 100 million yuan is an oxygen concentrator manufacturer that has suffered continuous losses, has an asset-liability ratio of over 77%, and has just been delisted from the New Third Board for only 8 days. Kangjuren landed on the New Third Board (code 874120) in April 2024 and planned to be listed on the Beijing Stock Exchange. However, due to the continued weakening of performance, it missed the application window. The investment and construction of the new base brought heavy financial pressure, and the listing was finally terminated on November 11, 2026.
After the epidemic, the demand for household respiratory equipment fell, and the industry was deeply involved in a price war. Corfu Medical chose to obtain production capacity and registration qualifications during the industry clearing process, fill in the shortcomings of oxygen concentrator manufacturing in the respiratory support sector, and compete for market share in the red sea of stock.
Low-priced acquisitions without performance commitments, and the target has continued losses and has high liabilities
The equity transferred to Corfu Medical comes from three parties: founders Guo Bensheng and Guo Benli and Anhui Oxygen Spirit Enterprise Management Consulting Co., Ltd., which together correspond to 60% of Kangjuren’s equity.
After the transaction was completed, Guo Bensheng's shareholding ratio dropped from 58.18% to 22.79%, and Guo Benli's shareholding dropped from 13.43% to 5%; Guo Bensheng held 71.5% of Anhui Oxygen Elf's shares and exited in full in this transaction. The remaining shares are held by three employee stock ownership platforms, Hefei Shuangge, Kangyi Times, and Kangsheng Times. The shareholding ratio remains unchanged, totaling 12.21%.
In other words, Guo Bensheng, Guo Benli and the three employee stock ownership platforms retain a total of 40% of the equity, and Corfu Medical has completed the consolidation in the form of absolute control.
At the pricing level, the company hired an appraisal agency to use July 31, 2026 as the base date, and used the asset-based method and the market method for valuation. Among them, the asset-based method assessed net assets at 126 million yuan, an increase of 49.55% over the book value; the market method assessed the value of all shareholders' equity at 166 million yuan, an increase of 97.64% over the book value.
The final transaction adopted the conclusion of the market method as the basis for pricing, with the price corresponding to 60% of the equity being 99.48 million yuan, and the overall valuation of the target being approximately 166 million yuan. Calculated based on the annualized revenue of 214 million yuan to 256 million yuan in the first ten months of 2026, the corresponding price-to-sales ratio of this acquisition is approximately 0.65 times; comparing the closing market value and rolling revenue on November 19, Corfu's own price-to-sales ratio is approximately 2.6 times. The pricing of this transaction is only one-quarter of the buyer's own valuation level.
The business trajectory of the target company reflects the cyclical fluctuations of the oxygen concentrator industry. Founded in 2011, Kangjuren focuses on respiratory products such as household oxygen concentrators and nebulizers. It owns brands such as Kangjuren and Oxygen Elf. The epidemic has driven an explosion in industry demand, and the company's revenue has been rising. Revenue will reach a peak of 473 million yuan in 2023, with net profit exceeding 50 million yuan and gross profit margin as high as 30.76%.
But when the economic turning point came, Kangju people chose to buck the trend and expand. In August 2024, the company obtained the construction permit for the Hefei Respiratory Health Industrial Park. The total planned investment in the project is approximately 400 million yuan. After reaching capacity, it will be able to produce a total of 1 million sets of oxygen concentrators, ventilators, and nebulizers annually. In 2025, the company's cash payment for the purchase and construction of fixed assets reached 95.8696 million yuan, and long-term borrowings also increased from 24.84 million yuan at the end of 2024 to 102 million yuan, an increase of 311%.
At the same time as the new production capacity was launched, the industry environment has taken a turn for the worse. After demand receded, the oxygen concentrator track fell into a situation of overcapacity and price wars. Kangjuren's revenue began to decline continuously. In 2024, revenue dropped to 321 million yuan, and further fell to 217 million yuan in 2025. It recorded a net loss of 20.1426 million yuan that year.
Losses come from the squeeze on both revenue and costs. Consumer demand has dropped, and market price bargaining continues to compress the income space of single products; however, rigid expenses such as depreciation of fixed assets brought about by the new base will not be reduced in line with the revenue contraction. In addition, online sales expenses and platform service fees remain high, profit margins continue to be eaten up, and the company turns from profit to loss.
In 2026, the company's operations will recover to a certain extent. In the first 10 months, it achieved revenue of 214 million yuan, which is close to the level of last year. The net loss narrowed to 11.5656 million yuan, and the operating cash flow turned positive to 56.971 million yuan, but the overall profit has not yet been achieved. As of the end of October 2026, Kangjuren's asset-liability ratio reached 77.44%, and debt pressure is still prominent.
It is worth noting that this transaction does not set any performance commitments and compensation terms, and the payment rhythm is relatively loose: 90% of the payment will be paid 3 working days after the completion of the industrial and commercial changes and the handover of the target, and the remaining 10% will be paid after 3 months of the first payment and confirmation that the target does not have undisclosed debts and other defaults. This means that Corfu Medical will directly bear the subsequent operating profits and losses of the target.
Strong channels meet weak manufacturing: production capacity puzzle in the red ocean
Corfu Medical is willing to take over this loss-making asset. The logic is that the target can form synergy with its existing business.
From the perspective of Corfu's own business structure, the respiratory support segment was previously a relatively weak link. Among the company's five major business segments in 2025, rehabilitation assistive devices, medical care, and health monitoring will all maintain growth. Only respiratory support revenue will slightly decrease by 0.67% year-on-year, accounting for only 7.83% of revenue.
Entering 2026, the company launched the AI ventilator C11, and jointly launched the Dabai X3 PRO lung disease ventilator with Rongxin, and the product echelon continued to improve. The company revealed at the investor exchange meeting at the end of October that ventilators are one of the categories in which the company has invested most intensively and fully verified in the past three years, and its growth logic has shifted from increasing the volume of single products to entering the triple driving stage of "product matrix + channels + overseas".
After the C11, the company will also launch the C12 flagship model, the P11 lung disease ventilator, the second-generation portable ventilator, and a variety of supporting respiratory masks, covering different needs from sleep breathing to lung disease treatment. Corfu's self-developed large models will also be applied to the ventilator category.
Corfu's advantages lie in the channel side. As one of the earliest medical device companies in China to deploy online self-operations, the company launched e-commerce layout and independently operated online stores in 2014. Offline, it covers chain pharmacy systems such as Baobin and Yifeng, and has cross-platform refined operation capabilities.
In 2025, online channel revenue will be 2.197 billion yuan, accounting for approximately 64.9% of total revenue. The online proportion has remained in the range of 65% to 70% for a long time, and will return to nearly 70% in the first three quarters of 2026; overseas business revenue in 2025 will be 299 million yuan, a year-on-year increase of 405.05%.
The strength of this set of channels reflects the weakness of the manufacturing end in terms of production capacity and new categories. In 2018, the company's self-produced products accounted for only 22.25% of its main revenue. Since then, it has relied on a package of acquisitions to "make up for the mistakes": from 2018 to 2020, it has successively acquired five factories: Shandong Yiyuan, Guizhou Meowen, Hefei Haijixing, Changsha Jiannuo, and Zhuhai Acorn. In 2022, it will acquire Acorn Trading and Back Beijia Brand for 177 million yuan. The structure of strong channels and weak manufacturing continues to improve, and the ventilator production capacity is supplemented by self-built and joint-stock Rongxin Medical; although the oxygen concentrator has the Oxylide brand, its own production capacity and registration certificate reserves cannot keep up with the pace of the respiratory support sector.
Kangju people just filled the gap in manufacturing. This manufacturer, which has been deeply involved in the field of oxygen concentrators for more than ten years, has 203 patents, including 39 invention patents. Its products cover a full range of categories such as small and medium-sized oxygen concentrators, plateau dispersion oxygen concentrators, atomizers, micro-hyperbaric oxygen chambers, etc. The newly built respiratory health industrial park will be able to produce 1 million sets of various types of respiratory equipment annually when it reaches full production, and has mature ODM manufacturing capabilities.
Looking over a longer period, the industry ceiling is a more fundamental constraint. After the overdraft growth of household oxygen concentrators during the epidemic, domestic demand has entered a stable period, and competition is dominated by the competition for stock share. The respiratory treatment segment of industry leader Yuyue Medical fell 13.33% year-on-year in the first half of 2026, which is enough to show that the overall prosperity of the track is limited. The essence of Corfu's acquisition is to compete for stock share in the Red Sea. (This article was first published on Titanium Media App, written by Jianwen Qianguan, author Cao Sanjin)
Respect for the original work, if you are qualified, you should be appreciated.
According to the real-name requirement of the Cybersecurity Law, please bind your mobile phone number before posting a comment.
Express
09:53
Trump: China-Russia-US presidents’ meeting “unprecedented” and “of great significance”
09:45
China has 27,000 "5G + Industrial Internet" projects, covering all 41 major industrial categories
09:44
The Security Council holds the ninth round of intention-to-hold votes on the selection of the next United Nations Secretary-General
09:39
France strengthens online supervision of 2027 presidential election
09:31
The S&P 500 fell for the seventh consecutive trading day, setting its longest losing streak since 2020.
09:28
Oracle said it has raised all the funds needed to fulfill its contract with OpenAI and expects free cash flow to exceed US$30 billion in fiscal 2029
09:27
The Nasdaq 100 index closed down 5.6%, wiping out $2.1 trillion in market value, erasing its gains this year.
09:22
U.S. stock market closing comments: The Dow and S&P 500 both retreated 10% from their previous highs, and Nvidia plummeted 14%.
09:20
OpenAI launches MedChemBench benchmark to evaluate AI-assisted drug development capabilities
09:18
Anthropic mathematician says he worked with Claude to prove Riemann Hypothesis
09:12
People familiar with the matter: The United States demands that Ukraine reach a peace agreement with Russia in early January next year
09:10
International gold prices continue to decline
09:08
The price of accumulated gold fell to "7", and banks have warned about the risks of fluctuations in the precious metal market
2026-11-20 22:59
Jinhui Group: Redemption of fixed-rate notes on Alibaba shares, involving HK$35.176 million
U.S. data center company shares fall
2026-11-20 22:58
The S&P 500 turned higher, erasing an early loss of about 0.6%.
2026-11-20 22:54
U.S. chipmaker shares fell, AMD fell 4.9%
2026-11-20 22:50
Anthropic's decline narrowed to less than 6%, after previously falling about 10%
2026-11-20 22:45
Nvidia fell to 4.5%, reporting at $139.430 per share, with a total market value of $3.36 trillion.
2026-11-20 22:34
The main fuel oil contract fell 4% during the day and is now at 3679.00 yuan.
Scan to download App




